The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Myovant Sciences Ltd. (MYOV) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$1.04, or +4.26%, to $25.48. Volume reached 26,667 shares, with price reaching a high of $25.65 and a low of $25.35. Most recently, Yahoo Finance reported about the stock as it publicized that Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares.
Myovant Sciences Ltd. is listed on the NYSE as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $25.48 and fluctuated between $25.70 as its day high and $23.77 as its day low. The current market capitalization of Myovant Sciences Ltd. is $2.39B. A total of 2.6 million shares were traded on the day, compared to an average of 867.71K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, MYOV has seen 1 BUY and 7 SELL insider trades, representing the acquisition of 124,780 and the disposition of 54,080 shares. Over the last 12 months, there were 8 BUYs and 23 SELLs from insiders. Insiders purchased 692,775 shares during that period but sold 147,274.
In the most recent transaction, Mehra Uneek sold 9,243 shares of MYOV for 18.86 per share on Sep 16. After the transaction, the Principal Financial Officer now owns 204,937 company shares. In a previous transaction on Aug 15, Lang Matthew sold 31,214 shares at 18.23 per share. MYOV shares that General Counsel & Corp. Secy. owns now total 363,966.
Among the insiders who sold shares, Lang Matthew disposed of 1,935 shares on Jul 18 at a per-share price of $12.87. This resulted in the General Counsel & Corp. Secy. holding 270,400 shares of MYOV after the transaction. In another insider transaction, Merendino Lauren sold 1,704 shares at $12.87 per share on Jul 18. Company shares held by the Chief Commercial Officer now total 173,249.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for MYOV in the last 3 months, the mean price target is $23.33 with high estimates of $27.00 and low estimates of $20.00. In terms of 52-week highs and lows, MYOV has a high of $25.04 and a low of $7.67.
As of this writing, MYOV has an earnings estimate of $-0.49 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of $-0.48 per share and a lower estimate of $-0.49. The company reported an EPS of $-0.22 in the last quarter, which was -69.23% lower than expectations of $-0.13.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MYOV is Buy with a score of 4.33. A total of 3 analysts rated the stock as Buy while 1 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.